[{"address1": "12278 Scripps Summit Drive", "city": "San Diego", "state": "CA", "zip": "92131", "country": "United States", "phone": "858 875 1800", "website": "https://www.fatetherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.", "fullTimeEmployees": 181, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bahram  Valamehr M.B.A., Ph.D.", "age": 47, "title": "President, CEO & Director", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 676600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cindy R. Tahl J.D.", "age": 51, "title": "Chief Legal & Compliance Officer and Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 644600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kamal  Adawi M.S., MBA", "age": 45, "title": "Chief Financial Officer", "yearBorn": 1979, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jessica  Francis", "title": "Vice President Of Human Resources & Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Victor  Hong", "title": "Vice President of Corporate Development & Finance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Henry", "age": 60, "title": "Senior Vice President of Clinical Operations", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tunde  Babalola Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yu  Cai J.D., Ph.D.", "title": "Head of Intellectual Property & Assistant General Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kate  Duvall", "title": "Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 3, "compensationRisk": 6, "shareHolderRightsRisk": 10, "overallRisk": 7, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.1, "open": 1.1, "dayLow": 1.1, "dayHigh": 1.1535, "regularMarketPreviousClose": 1.1, "regularMarketOpen": 1.1, "regularMarketDayLow": 1.1, "regularMarketDayHigh": 1.1535, "payoutRatio": 0.0, "beta": 2.336, "forwardPE": -0.67857146, "volume": 577832, "regularMarketVolume": 577832, "averageVolume": 2172874, "averageVolume10days": 1427140, "averageDailyVolume10Day": 1427140, "bid": 0.8136, "ask": 1.42, "bidSize": 2, "askSize": 2, "marketCap": 131501608, "fiftyTwoWeekLow": 0.66, "fiftyTwoWeekHigh": 3.39, "allTimeHigh": 121.16, "allTimeLow": 0.66, "priceToSalesTrailing12Months": 18.425333, "fiftyDayAverage": 1.235, "twoHundredDayAverage": 1.14665, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -4673390, "profitMargins": 0.0, "floatShares": 100820208, "sharesOutstanding": 115352289, "sharesShort": 7586108, "sharesShortPriorMonth": 7544331, "sharesShortPreviousMonthDate": 1760486400, "dateShortInterest": 1763078400, "sharesPercentSharesOut": 0.065799996, "heldPercentInsiders": 0.01771, "heldPercentInstitutions": 0.79482, "shortRatio": 3.55, "shortPercentOfFloat": 0.075, "impliedSharesOutstanding": 115352289, "bookValue": 2.029, "priceToBook": 0.5618531, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -156094000, "trailingEps": -1.33, "forwardEps": -1.68, "enterpriseToRevenue": -0.655, "enterpriseToEbitda": 0.032, "52WeekChange": -0.6283784, "SandP52WeekChange": 0.1265819, "quoteType": "EQUITY", "currentPrice": 1.14, "targetHighPrice": 8.0, "targetLowPrice": 2.0, "targetMeanPrice": 4.94444, "targetMedianPrice": 5.0, "recommendationMean": 2.08333, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 215423008, "totalCashPerShare": 1.868, "ebitda": -145343008, "totalDebt": 79245000, "quickRatio": 7.737, "currentRatio": 7.871, "totalRevenue": 7137000, "debtToEquity": 33.856, "revenuePerShare": 0.06, "returnOnAssets": -0.23847, "returnOnEquity": -0.52346003, "grossProfits": -92406000, "freeCashflow": -61314248, "operatingCashflow": -110569000, "revenueGrowth": -0.434, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -19.95118, "financialCurrency": "USD", "symbol": "FATE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NGM", "messageBoardId": "finmb_39268712", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1380634200000, "postMarketChangePercent": 1.7543843, "postMarketPrice": 1.16, "postMarketChange": 0.01999998, "regularMarketChange": 0.03999996, "regularMarketDayRange": "1.1 - 1.1535", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 2172874, "fiftyTwoWeekLowChange": 0.47999996, "fiftyTwoWeekLowChangePercent": 0.7272726, "fiftyTwoWeekRange": "0.66 - 3.39", "fiftyTwoWeekHighChange": -2.25, "fiftyTwoWeekHighChangePercent": -0.6637168, "fiftyTwoWeekChangePercent": -62.837837, "earningsTimestamp": 1763040600, "earningsTimestampStart": 1763040600, "earningsTimestampEnd": 1763040600, "earningsCallTimestampStart": 1715288400, "earningsCallTimestampEnd": 1715288400, "isEarningsDateEstimate": false, "corporateActions": [], "postMarketTime": 1764362892, "regularMarketTime": 1764363600, "regularMarketChangePercent": 3.6363602, "regularMarketPrice": 1.14, "marketState": "CLOSED", "shortName": "Fate Therapeutics, Inc.", "longName": "Fate Therapeutics, Inc.", "epsTrailingTwelveMonths": -1.33, "epsForward": -1.68, "epsCurrentYear": -1.14889, "priceEpsCurrentYear": -0.99226207, "fiftyDayAverageChange": -0.09500003, "fiftyDayAverageChangePercent": -0.0769231, "twoHundredDayAverageChange": -0.006649971, "twoHundredDayAverageChangePercent": -0.005799478, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.1 - Buy", "cryptoTradeable": false, "displayName": "Fate Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-29"}]